CF00C90323A
DRICUi014-A
General
Cell Line |
|
| hPSCreg Name | DRICUi014-A |
| Alternative name(s) |
CF00C90323A
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 12th January 2023 |
| Notes | Further anonymized information about the donor including demographic and clinical data will be made available on the Dementia Platforms UK data portal: https://portal.dementiasplatform.uk/ |
| User feedback | |
Provider |
|
| Generator | UK Dementia Research Institute, Cardiff University (DRICU) |
| Owner | UK Dementia Research Institute, Cardiff University (DRICU) |
| Distributors | |
| Derivation country | United Kingdom |
External Databases |
|
| BioSamples | SAMEA11604265 |
| Cellosaurus | CVCL_C1PK |
| Wikidata | Q114311330 |
| CLO | CLO_0104338 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Cell line can only be used in:
Disease research
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
Normal
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
External Databases (Donor) |
|
| BioSamples | SAMEA11604267 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Yes |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | Human Stem Cell Modelling of Brain Disease (AD-iPS), Cardiff University |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | Yes |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | No |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | No |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes |
| Does consent permit access to medical records of the donor? | Yes |
| Please describe how access is provided: | Relevant clinical information will be made available via a website hosted by Dementias Platform UK |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Wales REC 3 |
| Approval number | REC ID 12/WA/0052, IRAS ID 37622 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | |
| Approval number | |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | Yes |
| Further constraints on use | Use is restricted to disease research |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Thermo Fisher is the supplier of CytoTune™-iPS 2.0 Sendai Reprogramming Kit, used for iPSC reprogramming |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | Yes |
| Constraints for use or distribution | No commercial use, as described in the Limited use label License No: 518 CytoTune™ Technology for Products, owned by DNAVEC Corporation |
hIPSC Derivation
General |
|
| Source cell type |
T-LymphocyteA thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.
Synonyms
|
| Source cell origin |
BloodA liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
| Notes on reprogramming vector detection | virus undetectable at passage 11 |
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex | |||||||||||||||||||||
| Feeder cells |
No |
|||||||||||||||||||||
| Passage method |
Enzyme-free cell dissociation
EDTA
|
|||||||||||||||||||||
| O2 Concentration | 18 % | |||||||||||||||||||||
| CO2 Concentration | 5 % | |||||||||||||||||||||
| Medium |
Other medium:
Base medium: Advanced DMEM/F12 (Gibco Thermo Fisher 12634010)
Main protein source: Albumine Serum concentration: 0 % Supplements
|
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| TRA 1-60 |
Yes |
|||||
| NANOG |
Yes |
Morphology pictures
Differentiation Potency
| Marker | Expressed |
| C-X-C Chemokine Receptor Type 4 |
Yes |
| SRY-box transcription factor 17 |
Yes |
Morphology
IPMAR_DRICUi014-A_Endoderm.pdf
IPMAR_DRICUi014-A_Endoderm_ICC image
| Marker | Expressed |
| C-X-C Chemokine Receptor Type 4 |
Yes |
| BRACHYURY |
Yes |
Morphology
IPMAR_DRICUi014-A_Mesoderm.pdf
IPMAR_DRICUi014-A_Mesoderm_ICC image
| Marker | Expressed |
| Paired box 6 |
Yes |
| orthodenticle homeobox 2 |
Yes |
Morphology
IPMAR_DRICUi014-A_Ectoderm.pdf
IPMAR_DRICUi014-A_Ectoderm_ICC image
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
17
|
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
No gross abnormalities
Passage number: 17
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.